The potential utility of aripiprazole augmentation for major depressive disorder with mixed features specifier: A retrospective study
Chi-Un Pae 2, 4, 6*, Chnagsu Han 1, Sheng-Min Wang 2, 3, Won-Myong Bahk 2, Soo-Jung Lee 2, Ashwin A Patkar 4, Prakash S Masand 5
1Department of Psychiatry, Korea University College of Medicine, Seoul, Republic of Korea, 2Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea, 3International Health Care Center, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, 4Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA, 5Global Medical Education, New York, NY, USA, 6Cell Death Disease Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea
Received: October 19, 2018; Revised: December 19, 2018; Accepted: January 23, 2019; Published online: January 23, 2019.
© The Korean College of Neuropsychopharmacology. All rights reserved.

Abstract
Objective: The present study aimed to observe potential benefit of aripiprazole augmentation in the treatment of major depressive disorder with mixed specifier (MDDM) in naturalistic treatment setting.
Methods: Data were collected from MDDM patients using a retrospective chart review for 8 weeks (week -8 and week 0) in routine practice. All patients were on current antidepressants upon starting of aripiprazole. Patients were treated without restriction of doses of aripiprazole. The primary endpoint was the mean change of Montgomery–Åsberg Depression Rating Scale (MADRS) total scores along with various secondary endpoint measures.
Results: In total 38 patients were analyzed. The changes of MADRS, Clinical Global Impression(CGI)-severity, Young mania Rating Scale, Sheehan Disability Scale, and CGI-clinical benefit total scores from baseline to the endpoint were ̶ 7.1, ̶ 0.8, ̶ 4.9, ̶ 4.1 and ̶ 3.6, respectively (all P < 0.0001). At the endpoint, the responder and remitter rates by MADRS score criteria were approximately 32% and 21%, respectively.
Conclusion: The present findings have clearly shown the effectiveness and tolerability of aripiprazole augmentation for MDDM patients in routine practice. The present study warrants subsequent, adequately-powered, well-controlled studies for generalizability near future.
Keywords: Aripiprazole, Depressive disorder, Mixed specifier, Effectiveness, Tolerability


e-submission

Archives